GLP-1
-
U.S. FDA approves Eli Lilly’s GLP-1 oral weight-loss pillThe U.S. FDA said the drug was approved within 50 days of the company filing for approval, one of the fastest approval times for any drug.HealthApr 1
-
Could GLP-1 drugs help your mental health? New study finds a linkSemaglutide, the active ingredient in GLP-1 drugs, was associated with a lower risk of worsening mental health, a study published in Lancet Psychiatry found.HealthMar 20
-
Novo Nordisk says generic Ozempic, Wegovy will slow sales in CanadaNovo Nordisk says the expiration of its patents for some semaglutide GLP-1 drug treatments in markets like Canada will result in more generics and hurt sales.HealthFeb 4
![]()
-
Health Canada approves 1st GLP-1 daily pill. Here’s who can take itThe once-a-day semaglutide pill is approved for reducing the risk of heart disease and Type 2 diabetes, the company said in a statement Monday.CanadaJan 12
![]()
-
Many regain weight after stopping GLP-1 drugs, data shows. Here’s whyPeople on average regain weight at a rate of 0.4 kg/month after they stopped taking their weight loss medications, a review of 63 trials covering over 9,000 individuals showed.HealthJan 8
![]()
